MDXG
MiMedx Group Inc
NASDAQ: MDXG · HEALTHCARE · BIOTECHNOLOGY
$4.57
-0.65% today
Updated 2026-09-11
Market cap
$671.30M
P/E ratio
115.00
P/S ratio
1.89x
EPS (TTM)
$0.04
Dividend yield
—
52W range
$3 – $8
Volume
1.2M
WallStSmart proprietary scores
43
out of 100
Grade: D
Sell
Investment rating
6.7
Growth
B8.5
Quality
A3.5
Profitability
D4.7
Valuation
C3/9
Piotroski F-Score
Weak
4.2
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$7.40
+61.93%
12-Month target
$5.12
+12.04%
Intrinsic (DCF)
$41.87
Margin of safety
+87.56%
1 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 4.24 — safe zone
+ 87.56% below intrinsic value
+ Debt/equity 0.01x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 1.76%
- Negative free cash flow $-10.72M
- Revenue declining -34.70% QoQ
- P/E 115.00x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $267.84M | $321.48M | $348.88M | $418.63M | $355.17M |
| Net income | $-30.20M | $67.44M | $42.42M | $48.58M | $-14.84M |
| EPS | — | — | — | — | $0.04 |
| Free cash flow | $-20.58M | $24.79M | $64.52M | $72.97M | $-10.72M |
| Profit margin | -11.27% | 20.98% | 12.16% | 11.60% | 1.76% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-07-02 | DOUG, RICE | Sale | 12,749 | $3.95 |
| 2026-06-24 | MAERSK-MOLLER, KIMBERLY | Sale | 19,820 | $3.83 |
| 2026-06-10 | PUHY, DOROTHY E | Buy | 50,913 | $3.64 |
Peer comparison
Smart narrative
MiMedx Group Inc trades at $4.57. representing a P/E of 115.00x trailing earnings. Our Smart Value Score of 43/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 4.24, it sits in the safe zone. TTM revenue stands at $355.17M. with profit margins at 1.76%. Our DCF model estimates intrinsic value at $41.87.
Frequently asked questions
What is MiMedx Group Inc's stock price?
MiMedx Group Inc (MDXG) trades at $4.57, on a P/E of 115.0x and a P/S of 1.9x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is MiMedx Group Inc overvalued?
MiMedx Group Inc carries a Smart Value Score of 43/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $41.87 versus the $4.57 price, a 87.6% margin of safety on a cash flow basis.
What is the price target of MiMedx Group Inc (MDXG)?
The 12-month analyst consensus target is $7.40, about 61.9% above the current $4.57. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of MDXG by 2030?
Our research-backed model puts the 2030 base case at $6.36, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of MiMedx Group Inc (MDXG)?
Our DCF model estimates intrinsic value at $41.87, a +87.6% margin of safety versus today's $4.57. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is MiMedx Group Inc's revenue?
MiMedx Group Inc's trailing twelve-month revenue is $355.17M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
MiMedx Group Inc's Altman Z-Score is 4.24, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.89x
ROE2.89%
Beta1.42
50D MA$4.29
200D MA$4.69
Shares out0.15B
Float0.11B
Short ratio—
Avg volume1.2M
Performance
1 week+0.66%
1 month+7.48%
3 months+27.78%
YTD-32.05%
1 year-35.57%
3 years—
5 years—